Royalty Pharma forward PE RPRX
Share price divided by analysts' consensus earnings for the next twelve months, since 2020.
- Today, Nov 3, 2026
- 13.6×
- 6-year median
- 9.3×
- Against its 6-year history
- 81st
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 6.2× to 19.4×
- Peer median
- 20.9×
Royalty Pharma's forward PE is 13.6× as of Nov 3, 2026.
That is above its 6-year median of 9.3×, higher than on 81% of days in the last 6 years.
Over that time it ranged from 6.2× in Dec 2024 to 19.4× in Jun 2020.
The median for 10 healthcare stocks of a similar size is 20.9×.
Forward PE over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 13.4× | 7.8× | 13.6× |
| 2025 | 7.9× | 6.4× | 8.2× |
| 2024 | 6.3× | 6.2× | 7.9× |
| 2023 | 7.2× | 6.8× | 9.7× |
| 2022 | 9.1× | 9.1× | 13.4× |
| 2021 | 13.3× | 11.9× | 18.8× |
| 2020 | 18.1× | 14.3× | 19.4× |
Against its peers
Companies in Healthcare nearest Royalty Pharma's size, closest first, today.
| Company | Forward PE |
|---|---|
| RPRXRoyalty Pharma | 13.6× |
| BIIBBiogen | 19.0× |
| GEHCGE HealthCare Technologies | 15.4× |
| ONCBeOne Medicines | 45.0× |
| IQVIQVIA | 19.0× |
| ZTSZoetis | 13.4× |
| ILMNIllumina | 41.5× |
| MTDMettler-Toledo International | 34.6× |
| RMDResMed | 18.4× |
| WATWaters | 30.4× |
| MDLNMedline | 22.7× |
| Peer median | 20.9× |
Where Royalty Pharma ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on Royalty Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.